Research output per year
Research output per year
- 16 results
Search results
-
2025
Molecular basis of JAK kinase regulation guiding therapeutic approaches: Evaluating the JAK3 pseudokinase domain as a drug target
Virtanen, A., Kettunen, V., Musta, K., Räkköläinen, V., Knapp, S., Haikarainen, T. & Silvennoinen, O., Jan 2025, In: Advances in Biological Regulation. 95, 11 p., 101072.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
2024
Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity
Miao, Y., Virtanen, A., Zmajkovic, J., Hilpert, M., Skoda, R. C., Silvennoinen, O. & Haikarainen, T., 6 Jun 2024, In: Journal of Medicinal Chemistry. 67, 12, p. 10012–10024 13 p.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling
Abraham, B. G., Haikarainen, T., Vuorio, J., Girych, M., Virtanen, A. T., Kurttila, A., Karathanasis, C., Heilemann, M., Sharma, V., Vattulainen, I. T. & Silvennoinen, O. J., 8 Mar 2024, In: Science Advances. 10, 10, 15 p., eadl2097.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
2023
Development of an enzyme-coupled activity assay for Janus kinase 2 inhibitor screening
Pölläniemi, A., Virtanen, A., Silvennoinen, O. & Haikarainen, T., Jun 2023, In: SLAS discovery . 28, 4, p. 180-187 8 p.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling
Virtanen, A., Palmroth, M., Liukkonen, S., Kurttila, A., Haikarainen, T., Isomäki, P. & Silvennoinen, O., 2023, In: Arthritis & rheumatology. 75, 11, p. 2054-2061 8 p.Research output: Contribution to journal › Article › Scientific › peer-review
Open Access -
Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain
Virtanen, A. T., Haikarainen, T., Sampathkumar, P., Palmroth, M., Liukkonen, S., Liu, J., Nekhotiaeva, N., Hubbard, S. R. & Silvennoinen, O., Jan 2023, In: Pharmaceuticals. 16, 1, 17 p., 75.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation
Arwood, M. L., Liu, Y., Harkins, S. K., Weinstock, D. M., Yang, L., Stevenson, K. E., Plana, O. D., Dong, J., Cirka, H., Jones, K. L., Virtanen, A. T., Gupta, D. G., Ceas, A., Lawney, B., Yoda, A., Leahy, C., Hao, M., He, Z., Choi, H. G. & Wang, Y. & 5 others, , 15 Jun 2023, In: Cell chemical biology. 30, 6, p. 618-+ 27 p.Research output: Contribution to journal › Article › Scientific › peer-review
-
The RNA-binding protein Snd1/Tudor-SN regulates hypoxia-responsive gene expression
Saarikettu, J., Lehmusvaara, S., Pesu, M., Junttila, I., Partanen, J., Sipilä, P., Poutanen, M., Yang, J., Haikarainen, T. & Silvennoinen, O., May 2023, In: FASEB BioAdvances. 5, 5, p. 183-198 16 p.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
2022
Inhibition of RNA Binding in SND1 Increases the Levels of miR-1-3p and Sensitizes Cancer Cells to Navitoclax
Lehmusvaara, S., Haikarainen, T., Saarikettu, J., Nieto, G. M. & Silvennoinen, O., 1 Jul 2022, In: Cancers. 14, 13, 17 p., 3100.Research output: Contribution to journal › Article › Scientific › peer-review
Open Access -
Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response
Valli, A., Kuuliala, K., Virtanen, A., Kuuliala, A., Palmroth, M., Peltomaa, R., Vidqvist, K.-L., Leirisalo-Repo, M., Silvennoinen, O. & Isomäki, P., 15 Dec 2022, In: Clinical and Experimental Immunology. 210, 2, p. 141-150 10 p.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
2021
IRF2BP2 Mutation Is Associated with Increased STAT1 and STAT5 Activation in Two Family Members with Inflammatory Conditions and Lymphopenia
Palmroth, M., Viskari, H., Seppänen, M. R. J., Keskitalo, S., Virtanen, A., Varjosalo, M., Silvennoinen, O. & Isomäki, P., Aug 2021, In: Pharmaceuticals. 14, 8, 14 p., 797.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response
Palmroth, M., Kuuliala, K., Peltomaa, R., Virtanen, A., Kuuliala, A., Kurttila, A., Kinnunen, A., Leirisalo-Repo, M., Silvennoinen, O. & Isomäki, P., 24 Sept 2021, In: Frontiers in Immunology. 12, 12 p., 738481.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
2020
Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling
Raivola, J., Haikarainen, T. & Silvennoinen, O., Jan 2020, In: Cancers. 12, 1, 20 p., 78.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F(-) MPNs
Pastore, F., Krishnan, A., Hammaren, H. M., Silvennoinen, O., Yan, B. & Levine, R. L., 22 Sept 2020, In: Blood advances. 4, 18, p. 4554-4559 6 p.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
2019
Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations
Hammaren, H. M., Virtanen, A. T., Abraham, B. G., Peussa, H., Hubbard, S. R. & Silvennoinen, O., Apr 2019, In: Journal of Allergy and Clinical Immunology. 143, 4, p. 1549-+ 17 p.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile -
2018
Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain
Raivola, J., Hammaren, H. M., Virtanen, A. T., Bulleeraz, V., Ward, A. C. & Silvennoinen, O., 3 Dec 2018, In: Frontiers in oncology . 8, 14 p., 560.Research output: Contribution to journal › Article › Scientific › peer-review
Open AccessFile